Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:EWTXNASDAQ:HRMYNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$28.17-0.5%$29.45$23.42▼$62.58$1.63B0.77696,674 shs543,940 shsEWTXEdgewise Therapeutics$14.51+0.9%$18.67$10.60▼$38.12$1.52B0.361.16 million shs1.08 million shsHRMYHarmony Biosciences$33.46+4.4%$31.31$26.47▼$41.61$1.92B0.82581,925 shs1.17 million shsPRTAProthena$7.29-0.8%$11.39$7.17▼$25.42$392.40M0.11554,643 shs2.00 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.60%-5.12%+8.76%-18.16%-14.12%EWTXEdgewise Therapeutics+0.94%-11.52%+22.65%-49.42%-31.65%HRMYHarmony Biosciences+4.40%+13.54%+17.82%-13.72%+6.70%PRTAProthena-0.82%-20.76%-32.75%-49.52%-69.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.1876 of 5 stars3.32.00.04.23.20.81.9EWTXEdgewise Therapeutics3.0569 of 5 stars4.41.00.00.03.53.30.0HRMYHarmony Biosciences4.8571 of 5 stars4.53.00.00.03.43.34.4PRTAProthena3.6242 of 5 stars4.42.00.00.04.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.0098.79% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$40.22177.20% UpsideHRMYHarmony Biosciences 3.00Buy$52.3356.40% UpsidePRTAProthena 2.75Moderate Buy$55.00654.46% UpsideCurrent Analyst Ratings BreakdownLatest PRTA, AGIO, EWTX, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/3/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.003/18/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $44.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M44.05N/AN/A$27.02 per share1.04EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AHRMYHarmony Biosciences$714.73M2.69$2.50 per share13.38$7.97 per share4.20PRTAProthena$135.16M2.90N/AN/A$10.46 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.48N/AN/A1,845.92%-2.51%-2.26%N/AEWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.5115.8610.760.4717.98%23.16%14.24%N/APRTAProthena-$147.03M-$2.30N/AN/AN/A-90.50%-22.67%-19.68%5/8/2025 (Estimated)Latest PRTA, AGIO, EWTX, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45N/AN/AN/AN/AN/A5/8/2025Q1 2025PRTAProthena-$0.92N/AN/AN/A$8.18 millionN/A5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/25/2025Q4 2024HRMYHarmony Biosciences$0.74$0.85+$0.11$0.85$201.25 million$201.30 million2/20/2025Q4 2024AGIOAgios Pharmaceuticals-$1.69-$1.74-$0.05-$1.74$9.35 millionN/A2/20/2025Q4 2024PRTAProthena-$1.02-$1.08-$0.06-$1.08$7.53 million$2.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56EWTXEdgewise TherapeuticsN/A26.3526.35HRMYHarmony Biosciences0.283.243.20PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AEWTXEdgewise TherapeuticsN/AHRMYHarmony Biosciences86.23%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%EWTXEdgewise Therapeutics24.11%HRMYHarmony Biosciences23.60%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableEWTXEdgewise Therapeutics60104.77 million71.86 millionOptionableHRMYHarmony Biosciences20057.39 million39.47 millionOptionablePRTAProthena13053.83 million38.64 millionOptionablePRTA, AGIO, EWTX, and HRMY HeadlinesRecent News About These CompaniesProthena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8 at 4:39 AM | marketbeat.comProthena Q1 2025 Earnings PreviewMay 7 at 6:52 PM | msn.comA Look Ahead: Prothena Corp's Earnings ForecastMay 7 at 6:52 PM | benzinga.comInsiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458mMay 4, 2025 | finance.yahoo.comBoxer Capital Management LLC Invests $9.56 Million in Prothena Co. plc (NASDAQ:PRTA)May 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases Shares of 80,677 Prothena Co. plc (NASDAQ:PRTA)May 4, 2025 | marketbeat.comWilliam P. Scully Acquires 2,000 Shares of Prothena Co. plc (NASDAQ:PRTA) StockMay 3, 2025 | insidertrades.comPrice T Rowe Associates Inc. MD Trims Holdings in Prothena Co. plc (NASDAQ:PRTA)May 2, 2025 | marketbeat.comProthena to Report First Quarter 2025 Financial Results on May 8May 1, 2025 | businesswire.comProthena (NASDAQ:PRTA) Trading Down 2.4% - What's Next?April 30, 2025 | marketbeat.comBirchview Capital LP Buys 95,000 Shares of Prothena Co. plc (NASDAQ:PRTA)April 28, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Up 7.7% - Still a Buy?April 23, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 187,364 Shares of Prothena Co. plc (NASDAQ:PRTA)April 20, 2025 | marketbeat.comVanguard Group Inc. Boosts Stake in Prothena Co. plc (NASDAQ:PRTA)April 19, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Hits New 12-Month Low - What's Next?April 18, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 5.4% - What's Next?April 17, 2025 | marketbeat.comNorges Bank Invests $796,000 in Prothena Co. plc (NASDAQ:PRTA)April 14, 2025 | marketbeat.comFederated Hermes Inc. Increases Stock Holdings in Prothena Co. plc (NASDAQ:PRTA)April 13, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by BrokeragesApril 13, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Invests $621,000 in Prothena Co. plc (NASDAQ:PRTA)April 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 9.6% - What's Next?April 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTA, AGIO, EWTX, and HRMY Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$28.17 -0.15 (-0.53%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$28.22 +0.04 (+0.16%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Edgewise Therapeutics NASDAQ:EWTX$14.51 +0.13 (+0.90%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$14.24 -0.27 (-1.86%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Harmony Biosciences NASDAQ:HRMY$33.46 +1.41 (+4.40%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$33.18 -0.28 (-0.82%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Prothena NASDAQ:PRTA$7.29 -0.06 (-0.82%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$7.48 +0.20 (+2.67%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
